Catalyst Awardee

Project Description

Zhiwei Wang, MD |Peking Union Medical College Hospital; Ruirui Xing, PhD;Guizhi Shen, PhD; Sihang Cheng, MD;
Competition Sponsor:
 Chinese Academy of Medical Sciences
Awardee Year: 2023


Senile patients with liver cancer lack effective treatment methods for the reason that the majority of senile patients have high operation risk. This study aims to address the problem of difficult-to-remove and easily recurrent and metastatic local lesions encountered in the clinical treatment of elderly and middle-aged liver cancer, by focusing on the construction of a immune hydrogel system and minimally invasive drug delivery. This study used an orthotopic model of hepatocellular carcinoma to study the feasibility of the treatment mode of arterial embolization combined with chemoimmunotherapy in the treatment of mid- to late-stage liver cancer under digital subtraction angiography (DSA). The hydrogel system carrying clinical chemotherapeutic agents was accurately and targetedly delivered to the nutrient artery of liver cancer. On the one hand, through the targeted delivery of chemotherapy drugs, the in situ liver cancer cells are effectively “killed”; At the same time, the special rheological properties of immunoactive peptide hydrogel form embolism in tumor blood vessels, and “starve” tumor cells by cutting off blood supply, so as to achieve effective tumor shrinkage effect of in situ liver cancer. Immunoactive peptide hydrogels exert a long-lasting and synergistic immunomodulatory effect by continuously releasing active peptide components to prevent the recurrence and metastasis of liver cancer. This project expects to complete the dual role of vascular embolism superimposed on continuous immunotherapy for middle and advanced liver cancer on the newly constructed self-assembled immunoactive peptide hydrogel platform, realize the dual efficacy of ablation of primary tumor and prevention of recurrence and metastasis.

Sign up for updates